[Drug-induced pseudoaldosteronism].
Miyamori
Isamu
I
Third Department of Medicine, University of Fukui Faculty of Medical Sciences.
D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000037:antagonists & inhibitors; D042241:Early Diagnosis; D006035:Glycyrrhiza / Q000009:adverse effects*; D019695:Glycyrrhizic Acid / Q000009:adverse effects*; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D019695:Glycyrrhizic Acid; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2